Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 12/20 | 0.60 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.60 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012616 | 0.90 | MAPK13 (0.66) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL1793950 | 0.89 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL4510854 | 0.89 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL1015668 | 0.88 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL1012411 | 0.88 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL1013792 | 0.88 | RAF1 (0.52) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL1012863 | 0.88 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL13678580 | 0.87 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| Carbamic Acid SCHEMBL1780358 | 0.87 | MAPK13 (0.62) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL5087248 | 0.86 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219489-A2 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Washington University (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3074396-B1 | 1-(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LTD (GB) | 2019-05-01 | — | — | EP | disclosed |
| EP-3074396-B1 | 1-(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-[2-FLUORO-4-[(3-OXO-4H-PYRIDO[2, 3-B]PYRAZIN-8-YL)OXY]PHENYL]UREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LTD (GB) | 2019-05-01 | — | — | EP | disclosed |
| US-10167282-B2 | 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
| US-10167282-B2 | 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
| US-10100053-B2 | Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-b]pyrazin-3-one derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-10-16 | — | — | US | disclosed |
| EP-3074395-B1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2018-08-22 | — | — | EP | disclosed |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-8618289-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-2044053-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | MAPK14 145/4885MAPK13 117/4885MAPK12 139/4885 |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885MAPK13 1/4885MAPK12 2/4885 |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPK14 80/4885MAPK13 76/4885MAPK12 124/4885 |
| US-10100053-B2 | Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-b]pyrazin-3-one derivatives | PAM, PDXK, GRHPR | MAPK14 2529/4885MAPK13 956/4885MAPK12 1964/4885 |
| US-10167282-B2 | 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer | BRAF, NRAS, LCK | MAPK14 80/4885MAPK13 70/4885MAPK12 67/4885 |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885MAPK13 1/4885MAPK12 2/4885 |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPK14 145/4885MAPK13 117/4885MAPK12 139/4885 |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | UMPS, SLC14A1, CPS1 | MAPK14 3645/4885MAPK13 3641/4885MAPK12 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.